nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—Organic Cation Transporter 2 Inhibitors—Crizotinib—lung cancer	0.563	1	CiPCiCtD
Dolutegravir—UGT1A1—lung cancer	0.229	1	CbGaD
Dolutegravir—UGT1A1—Erlotinib—lung cancer	0.0453	0.381	CbGbCtD
Dolutegravir—UGT1A1—Irinotecan—lung cancer	0.0409	0.344	CbGbCtD
Dolutegravir—UGT1A1—Etoposide—lung cancer	0.0327	0.275	CbGbCtD
Dolutegravir—POU2F2—mammary gland—lung cancer	0.00511	0.466	CbGeAlD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—RRAD—lung cancer	0.00418	0.12	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—AXL—lung cancer	0.00317	0.0911	CbGpPWpGaD
Dolutegravir—POU2F2—bronchus—lung cancer	0.0028	0.256	CbGeAlD
Dolutegravir—POU2F2—lung—lung cancer	0.00181	0.165	CbGeAlD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—TP63—lung cancer	0.00175	0.0505	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—SFN—lung cancer	0.0015	0.0431	CbGpPWpGaD
Dolutegravir—POU2F2—lymph node—lung cancer	0.00124	0.113	CbGeAlD
Dolutegravir—POU2F2—Ectoderm Differentiation—HMGB2—lung cancer	0.00114	0.0327	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCC3—lung cancer	0.00103	0.0297	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—HES1—lung cancer	0.000861	0.0248	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.00084	0.0242	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—SOX2—lung cancer	0.000653	0.0188	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.000637	0.0183	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—SOX2—lung cancer	0.000592	0.017	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.000573	0.0165	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTA1—lung cancer	0.000546	0.0157	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—ABCG2—lung cancer	0.000538	0.0155	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—lung cancer	0.000526	0.0151	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—lung cancer	0.000516	0.0149	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TF—lung cancer	0.000503	0.0145	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—MDM2—lung cancer	0.000501	0.0144	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAP2K1—lung cancer	0.000424	0.0122	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—RAF1—lung cancer	0.000376	0.0108	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—GSTA2—lung cancer	0.000357	0.0103	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—AVP—lung cancer	0.000349	0.01	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—NQO1—lung cancer	0.000348	0.01	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCC3—lung cancer	0.000341	0.00981	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HES1—lung cancer	0.00033	0.00949	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL10—lung cancer	0.000328	0.00944	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—JUN—lung cancer	0.000328	0.00943	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—lung cancer	0.000317	0.00912	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—lung cancer	0.000276	0.00795	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—lung cancer	0.000271	0.0078	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—GSTA2—lung cancer	0.000267	0.00769	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—lung cancer	0.000267	0.00767	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP2A6—lung cancer	0.000261	0.00752	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A1—lung cancer	0.000253	0.00727	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—APC—lung cancer	0.000242	0.00697	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—lung cancer	0.000233	0.00671	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—lung cancer	0.000227	0.00654	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6R—lung cancer	0.000226	0.00651	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CREBBP—lung cancer	0.000226	0.0065	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—lung cancer	0.000224	0.00644	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM2—lung cancer	0.000221	0.00637	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—CNDP2—lung cancer	0.000221	0.00637	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—lung cancer	0.000207	0.00595	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—lung cancer	0.000183	0.00526	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—lung cancer	0.000179	0.00516	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA3—lung cancer	0.000178	0.00513	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000173	0.00499	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CASP3—lung cancer	0.000172	0.00494	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—JUN—lung cancer	0.000167	0.0048	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—lung cancer	0.000164	0.00473	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA4—lung cancer	0.000163	0.0047	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUNB—lung cancer	0.000163	0.00469	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA2—lung cancer	0.000159	0.00458	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—PRDX1—lung cancer	0.000157	0.00452	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—EP300—lung cancer	0.000154	0.00443	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA1—lung cancer	0.000153	0.00441	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—lung cancer	0.000148	0.00425	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM2—lung cancer	0.000148	0.00425	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—lung cancer	0.000146	0.00419	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CNDP2—lung cancer	0.00013	0.00373	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTM2—lung cancer	0.00013	0.00373	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM2—lung cancer	0.000128	0.00367	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—lung cancer	0.000127	0.00364	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—HPGDS—lung cancer	0.000121	0.00349	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—lung cancer	0.000119	0.00343	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA3—lung cancer	0.000119	0.00342	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—lung cancer	0.000118	0.00338	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CYP2A7—lung cancer	0.000117	0.00337	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GCLC—lung cancer	0.000116	0.00335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP2A7—lung cancer	0.000116	0.00332	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—KEAP1—lung cancer	0.000112	0.00322	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA4—lung cancer	0.000109	0.00313	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA2—lung cancer	0.000106	0.00305	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA3—lung cancer	0.000104	0.003	CbGpPWpGaD
Dolutegravir—Diarrhoea—Teniposide—lung cancer	0.000104	0.00239	CcSEcCtD
Dolutegravir—Hyperglycaemia—Paclitaxel—lung cancer	0.000103	0.00236	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTA3—lung cancer	0.000103	0.00296	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Docetaxel—lung cancer	0.000102	0.00235	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA1—lung cancer	0.000102	0.00294	CbGpPWpGaD
Dolutegravir—Renal failure—Etoposide—lung cancer	0.000102	0.00234	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—lung cancer	0.000102	0.00234	CcSEcCtD
Dolutegravir—Immune system disorder—Irinotecan—lung cancer	0.000101	0.00232	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—ABCC3—lung cancer	0.000101	0.00291	CbGpPWpGaD
Dolutegravir—Insomnia—Erlotinib—lung cancer	0.000101	0.00232	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—lung cancer	0.000101	0.0029	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Cisplatin—lung cancer	0.000101	0.00231	CcSEcCtD
Dolutegravir—Renal failure—Paclitaxel—lung cancer	0.0001	0.0023	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.0001	0.0023	CcSEcCtD
Dolutegravir—Urethral disorder—Cisplatin—lung cancer	9.99e-05	0.00229	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—lung cancer	9.94e-05	0.00228	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Docetaxel—lung cancer	9.9e-05	0.00227	CcSEcCtD
Dolutegravir—Immune system disorder—Gemcitabine—lung cancer	9.88e-05	0.00226	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Etoposide—lung cancer	9.84e-05	0.00225	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Topotecan—lung cancer	9.76e-05	0.00224	CcSEcCtD
Dolutegravir—Fatigue—Topotecan—lung cancer	9.75e-05	0.00223	CcSEcCtD
Dolutegravir—Vomiting—Teniposide—lung cancer	9.7e-05	0.00222	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Erlotinib—lung cancer	9.66e-05	0.00221	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Paclitaxel—lung cancer	9.65e-05	0.00221	CcSEcCtD
Dolutegravir—Fatigue—Erlotinib—lung cancer	9.64e-05	0.00221	CcSEcCtD
Dolutegravir—Flatulence—Irinotecan—lung cancer	9.63e-05	0.00221	CcSEcCtD
Dolutegravir—Rash—Teniposide—lung cancer	9.62e-05	0.0022	CcSEcCtD
Dolutegravir—Dermatitis—Teniposide—lung cancer	9.61e-05	0.0022	CcSEcCtD
Dolutegravir—Headache—Teniposide—lung cancer	9.56e-05	0.00219	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTA4—lung cancer	9.55e-05	0.00275	CbGpPWpGaD
Dolutegravir—Abnormal dreams—Doxorubicin—lung cancer	9.53e-05	0.00218	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vinblastine—lung cancer	9.52e-05	0.00218	CcSEcCtD
Dolutegravir—Nervous system disorder—Vinorelbine—lung cancer	9.49e-05	0.00217	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTA4—lung cancer	9.42e-05	0.00271	CbGpPWpGaD
Dolutegravir—Skin disorder—Vinorelbine—lung cancer	9.39e-05	0.00215	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTA2—lung cancer	9.3e-05	0.00268	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Topotecan—lung cancer	9.25e-05	0.00212	CcSEcCtD
Dolutegravir—Urinary tract disorder—Etoposide—lung cancer	9.22e-05	0.00211	CcSEcCtD
Dolutegravir—Immune system disorder—Cisplatin—lung cancer	9.21e-05	0.00211	CcSEcCtD
Dolutegravir—Abdominal pain—Vinblastine—lung cancer	9.2e-05	0.00211	CcSEcCtD
Dolutegravir—Urethral disorder—Etoposide—lung cancer	9.16e-05	0.0021	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Erlotinib—lung cancer	9.15e-05	0.0021	CcSEcCtD
Dolutegravir—Neutropenia—Docetaxel—lung cancer	9.07e-05	0.00208	CcSEcCtD
Dolutegravir—Nausea—Teniposide—lung cancer	9.06e-05	0.00208	CcSEcCtD
Dolutegravir—Urinary tract disorder—Paclitaxel—lung cancer	9.04e-05	0.00207	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NFE2L2—lung cancer	9.02e-05	0.00259	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA1—lung cancer	8.98e-05	0.00258	CbGpPWpGaD
Dolutegravir—Urethral disorder—Paclitaxel—lung cancer	8.98e-05	0.00206	CcSEcCtD
Dolutegravir—Abdominal pain—Topotecan—lung cancer	8.94e-05	0.00205	CcSEcCtD
Dolutegravir—Abdominal pain—Erlotinib—lung cancer	8.84e-05	0.00203	CcSEcCtD
Dolutegravir—Vertigo—Irinotecan—lung cancer	8.78e-05	0.00201	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—lung cancer	8.77e-05	0.00201	CcSEcCtD
Dolutegravir—Flatulence—Cisplatin—lung cancer	8.74e-05	0.002	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFA—lung cancer	8.6e-05	0.00248	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Vinblastine—lung cancer	8.58e-05	0.00196	CcSEcCtD
Dolutegravir—Renal failure—Docetaxel—lung cancer	8.5e-05	0.00195	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1C1—lung cancer	8.48e-05	0.00244	CbGpPWpGaD
Dolutegravir—Immune system disorder—Etoposide—lung cancer	8.44e-05	0.00193	CcSEcCtD
Dolutegravir—Asthenia—Vinblastine—lung cancer	8.35e-05	0.00191	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Vinorelbine—lung cancer	8.35e-05	0.00191	CcSEcCtD
Dolutegravir—Fatigue—Vinorelbine—lung cancer	8.34e-05	0.00191	CcSEcCtD
Dolutegravir—Hypersensitivity—Topotecan—lung cancer	8.33e-05	0.00191	CcSEcCtD
Dolutegravir—Immune system disorder—Paclitaxel—lung cancer	8.27e-05	0.00189	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Docetaxel—lung cancer	8.18e-05	0.00187	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—lung cancer	8.15e-05	0.00235	CbGpPWpGaD
Dolutegravir—Asthenia—Topotecan—lung cancer	8.11e-05	0.00186	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	8.05e-05	0.00184	CcSEcCtD
Dolutegravir—Asthenia—Erlotinib—lung cancer	8.03e-05	0.00184	CcSEcCtD
Dolutegravir—Mental disorder—Paclitaxel—lung cancer	8.02e-05	0.00184	CcSEcCtD
Dolutegravir—Pruritus—Topotecan—lung cancer	8e-05	0.00183	CcSEcCtD
Dolutegravir—Diarrhoea—Vinblastine—lung cancer	7.96e-05	0.00182	CcSEcCtD
Dolutegravir—Pruritus—Erlotinib—lung cancer	7.91e-05	0.00181	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vinorelbine—lung cancer	7.91e-05	0.00181	CcSEcCtD
Dolutegravir—Flatulence—Paclitaxel—lung cancer	7.85e-05	0.0018	CcSEcCtD
Dolutegravir—Nervous system disorder—Irinotecan—lung cancer	7.82e-05	0.00179	CcSEcCtD
Dolutegravir—Hepatitis—Docetaxel—lung cancer	7.76e-05	0.00178	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—CYP2A6—lung cancer	7.76e-05	0.00223	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GCLC—lung cancer	7.76e-05	0.00223	CbGpPWpGaD
Dolutegravir—Diarrhoea—Topotecan—lung cancer	7.74e-05	0.00177	CcSEcCtD
Dolutegravir—Dizziness—Vinblastine—lung cancer	7.7e-05	0.00176	CcSEcCtD
Dolutegravir—Urinary tract disorder—Docetaxel—lung cancer	7.67e-05	0.00176	CcSEcCtD
Dolutegravir—Diarrhoea—Erlotinib—lung cancer	7.65e-05	0.00175	CcSEcCtD
Dolutegravir—Abdominal pain—Vinorelbine—lung cancer	7.65e-05	0.00175	CcSEcCtD
Dolutegravir—Nervous system disorder—Gemcitabine—lung cancer	7.62e-05	0.00175	CcSEcCtD
Dolutegravir—Urethral disorder—Docetaxel—lung cancer	7.61e-05	0.00174	CcSEcCtD
Dolutegravir—Skin disorder—Gemcitabine—lung cancer	7.55e-05	0.00173	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	7.5e-05	0.00172	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—lung cancer	7.49e-05	0.00216	CbGpPWpGaD
Dolutegravir—Dizziness—Topotecan—lung cancer	7.48e-05	0.00171	CcSEcCtD
Dolutegravir—Vomiting—Vinblastine—lung cancer	7.4e-05	0.0017	CcSEcCtD
Dolutegravir—Dizziness—Erlotinib—lung cancer	7.4e-05	0.00169	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—lung cancer	7.36e-05	0.00169	CcSEcCtD
Dolutegravir—Vertigo—Etoposide—lung cancer	7.3e-05	0.00167	CcSEcCtD
Dolutegravir—Headache—Vinblastine—lung cancer	7.29e-05	0.00167	CcSEcCtD
Dolutegravir—Insomnia—Irinotecan—lung cancer	7.21e-05	0.00165	CcSEcCtD
Dolutegravir—Vomiting—Topotecan—lung cancer	7.19e-05	0.00165	CcSEcCtD
Dolutegravir—Vertigo—Paclitaxel—lung cancer	7.16e-05	0.00164	CcSEcCtD
Dolutegravir—Rash—Topotecan—lung cancer	7.13e-05	0.00163	CcSEcCtD
Dolutegravir—Hypersensitivity—Vinorelbine—lung cancer	7.13e-05	0.00163	CcSEcCtD
Dolutegravir—Dermatitis—Topotecan—lung cancer	7.12e-05	0.00163	CcSEcCtD
Dolutegravir—Vomiting—Erlotinib—lung cancer	7.11e-05	0.00163	CcSEcCtD
Dolutegravir—Nervous system disorder—Cisplatin—lung cancer	7.1e-05	0.00163	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—HPGDS—lung cancer	7.1e-05	0.00204	CbGpPWpGaD
Dolutegravir—Headache—Topotecan—lung cancer	7.08e-05	0.00162	CcSEcCtD
Dolutegravir—Rash—Erlotinib—lung cancer	7.05e-05	0.00162	CcSEcCtD
Dolutegravir—Dermatitis—Erlotinib—lung cancer	7.05e-05	0.00161	CcSEcCtD
Dolutegravir—Skin disorder—Cisplatin—lung cancer	7.04e-05	0.00161	CcSEcCtD
Dolutegravir—Insomnia—Gemcitabine—lung cancer	7.03e-05	0.00161	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—lung cancer	7.01e-05	0.00161	CcSEcCtD
Dolutegravir—Headache—Erlotinib—lung cancer	7.01e-05	0.00161	CcSEcCtD
Dolutegravir—Asthenia—Vinorelbine—lung cancer	6.94e-05	0.00159	CcSEcCtD
Dolutegravir—Nausea—Vinblastine—lung cancer	6.91e-05	0.00158	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Irinotecan—lung cancer	6.89e-05	0.00158	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—lung cancer	6.88e-05	0.00198	CbGpPWpGaD
Dolutegravir—Fatigue—Irinotecan—lung cancer	6.88e-05	0.00158	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	6.87e-05	0.00157	CcSEcCtD
Dolutegravir—Pruritus—Vinorelbine—lung cancer	6.84e-05	0.00157	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GCLC—lung cancer	6.8e-05	0.00196	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CYP2A6—lung cancer	6.8e-05	0.00196	CbGpPWpGaD
Dolutegravir—Mental disorder—Docetaxel—lung cancer	6.8e-05	0.00156	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	6.74e-05	0.00154	CcSEcCtD
Dolutegravir—Nausea—Topotecan—lung cancer	6.72e-05	0.00154	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Gemcitabine—lung cancer	6.71e-05	0.00154	CcSEcCtD
Dolutegravir—Abdominal discomfort—Methotrexate—lung cancer	6.7e-05	0.00153	CcSEcCtD
Dolutegravir—Fatigue—Gemcitabine—lung cancer	6.7e-05	0.00153	CcSEcCtD
Dolutegravir—Nausea—Erlotinib—lung cancer	6.64e-05	0.00152	CcSEcCtD
Dolutegravir—Diarrhoea—Vinorelbine—lung cancer	6.62e-05	0.00152	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—lung cancer	6.58e-05	0.00189	CbGpPWpGaD
Dolutegravir—Blood creatinine increased—Doxorubicin—lung cancer	6.56e-05	0.0015	CcSEcCtD
Dolutegravir—Neutropenia—Methotrexate—lung cancer	6.54e-05	0.0015	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Irinotecan—lung cancer	6.52e-05	0.00149	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NQO1—lung cancer	6.52e-05	0.00188	CbGpPWpGaD
Dolutegravir—Skin disorder—Etoposide—lung cancer	6.45e-05	0.00148	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—lung cancer	6.4e-05	0.00184	CbGpPWpGaD
Dolutegravir—Dizziness—Vinorelbine—lung cancer	6.4e-05	0.00147	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—lung cancer	6.4e-05	0.00146	CcSEcCtD
Dolutegravir—Nervous system disorder—Paclitaxel—lung cancer	6.38e-05	0.00146	CcSEcCtD
Dolutegravir—Skin disorder—Paclitaxel—lung cancer	6.32e-05	0.00145	CcSEcCtD
Dolutegravir—Abdominal pain—Irinotecan—lung cancer	6.31e-05	0.00144	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Cisplatin—lung cancer	6.25e-05	0.00143	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—lung cancer	6.18e-05	0.00141	CcSEcCtD
Dolutegravir—Vomiting—Vinorelbine—lung cancer	6.15e-05	0.00141	CcSEcCtD
Dolutegravir—Renal failure—Methotrexate—lung cancer	6.13e-05	0.0014	CcSEcCtD
Dolutegravir—Rash—Vinorelbine—lung cancer	6.1e-05	0.0014	CcSEcCtD
Dolutegravir—Dermatitis—Vinorelbine—lung cancer	6.09e-05	0.0014	CcSEcCtD
Dolutegravir—Headache—Vinorelbine—lung cancer	6.06e-05	0.00139	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—lung cancer	5.9e-05	0.0017	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Methotrexate—lung cancer	5.89e-05	0.00135	CcSEcCtD
Dolutegravir—Insomnia—Paclitaxel—lung cancer	5.88e-05	0.00135	CcSEcCtD
Dolutegravir—Hypersensitivity—Irinotecan—lung cancer	5.88e-05	0.00135	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2E1—lung cancer	5.78e-05	0.00166	CbGpPWpGaD
Dolutegravir—Nausea—Vinorelbine—lung cancer	5.75e-05	0.00132	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—lung cancer	5.74e-05	0.00165	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Etoposide—lung cancer	5.73e-05	0.00131	CcSEcCtD
Dolutegravir—Asthenia—Irinotecan—lung cancer	5.72e-05	0.00131	CcSEcCtD
Dolutegravir—Fatigue—Etoposide—lung cancer	5.72e-05	0.00131	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	5.71e-05	0.00131	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP2E1—lung cancer	5.7e-05	0.00164	CbGpPWpGaD
Dolutegravir—Neutropenia—Doxorubicin—lung cancer	5.66e-05	0.0013	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Paclitaxel—lung cancer	5.62e-05	0.00129	CcSEcCtD
Dolutegravir—Fatigue—Paclitaxel—lung cancer	5.61e-05	0.00128	CcSEcCtD
Dolutegravir—Hepatitis—Methotrexate—lung cancer	5.59e-05	0.00128	CcSEcCtD
Dolutegravir—Asthenia—Gemcitabine—lung cancer	5.58e-05	0.00128	CcSEcCtD
Dolutegravir—Urinary tract disorder—Methotrexate—lung cancer	5.52e-05	0.00127	CcSEcCtD
Dolutegravir—Pruritus—Gemcitabine—lung cancer	5.5e-05	0.00126	CcSEcCtD
Dolutegravir—Urethral disorder—Methotrexate—lung cancer	5.48e-05	0.00126	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—lung cancer	5.46e-05	0.00125	CcSEcCtD
Dolutegravir—Diarrhoea—Irinotecan—lung cancer	5.46e-05	0.00125	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—lung cancer	5.44e-05	0.00156	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Etoposide—lung cancer	5.43e-05	0.00124	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—lung cancer	5.41e-05	0.00124	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—lung cancer	5.36e-05	0.00123	CcSEcCtD
Dolutegravir—Hypersensitivity—Cisplatin—lung cancer	5.34e-05	0.00122	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Paclitaxel—lung cancer	5.32e-05	0.00122	CcSEcCtD
Dolutegravir—Diarrhoea—Gemcitabine—lung cancer	5.32e-05	0.00122	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—lung cancer	5.3e-05	0.00121	CcSEcCtD
Dolutegravir—Dizziness—Irinotecan—lung cancer	5.28e-05	0.00121	CcSEcCtD
Dolutegravir—Abdominal pain—Etoposide—lung cancer	5.25e-05	0.0012	CcSEcCtD
Dolutegravir—Asthenia—Cisplatin—lung cancer	5.2e-05	0.00119	CcSEcCtD
Dolutegravir—Abdominal pain—Paclitaxel—lung cancer	5.14e-05	0.00118	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—lung cancer	5.1e-05	0.00117	CcSEcCtD
Dolutegravir—Vomiting—Irinotecan—lung cancer	5.07e-05	0.00116	CcSEcCtD
Dolutegravir—Immune system disorder—Methotrexate—lung cancer	5.05e-05	0.00116	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—lung cancer	5.03e-05	0.00145	CbGpPWpGaD
Dolutegravir—Rash—Irinotecan—lung cancer	5.03e-05	0.00115	CcSEcCtD
Dolutegravir—Dermatitis—Irinotecan—lung cancer	5.03e-05	0.00115	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—lung cancer	5e-05	0.00144	CbGpPWpGaD
Dolutegravir—Headache—Irinotecan—lung cancer	5e-05	0.00114	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—lung cancer	4.99e-05	0.00114	CcSEcCtD
Dolutegravir—Diarrhoea—Cisplatin—lung cancer	4.96e-05	0.00114	CcSEcCtD
Dolutegravir—Vomiting—Gemcitabine—lung cancer	4.94e-05	0.00113	CcSEcCtD
Dolutegravir—Mental disorder—Methotrexate—lung cancer	4.9e-05	0.00112	CcSEcCtD
Dolutegravir—Rash—Gemcitabine—lung cancer	4.9e-05	0.00112	CcSEcCtD
Dolutegravir—Dermatitis—Gemcitabine—lung cancer	4.89e-05	0.00112	CcSEcCtD
Dolutegravir—Hypersensitivity—Etoposide—lung cancer	4.89e-05	0.00112	CcSEcCtD
Dolutegravir—Headache—Gemcitabine—lung cancer	4.87e-05	0.00112	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—lung cancer	4.84e-05	0.00111	CcSEcCtD
Dolutegravir—Hypersensitivity—Paclitaxel—lung cancer	4.79e-05	0.0011	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—lung cancer	4.78e-05	0.0011	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—lung cancer	4.77e-05	0.00137	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Docetaxel—lung cancer	4.76e-05	0.00109	CcSEcCtD
Dolutegravir—Asthenia—Etoposide—lung cancer	4.76e-05	0.00109	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—lung cancer	4.75e-05	0.00109	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—lung cancer	4.75e-05	0.00109	CcSEcCtD
Dolutegravir—Nausea—Irinotecan—lung cancer	4.74e-05	0.00109	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—lung cancer	4.7e-05	0.00135	CbGpPWpGaD
Dolutegravir—Pruritus—Etoposide—lung cancer	4.69e-05	0.00108	CcSEcCtD
Dolutegravir—Asthenia—Paclitaxel—lung cancer	4.67e-05	0.00107	CcSEcCtD
Dolutegravir—Nausea—Gemcitabine—lung cancer	4.62e-05	0.00106	CcSEcCtD
Dolutegravir—Vomiting—Cisplatin—lung cancer	4.61e-05	0.00105	CcSEcCtD
Dolutegravir—Pruritus—Paclitaxel—lung cancer	4.6e-05	0.00105	CcSEcCtD
Dolutegravir—Rash—Cisplatin—lung cancer	4.57e-05	0.00105	CcSEcCtD
Dolutegravir—Dermatitis—Cisplatin—lung cancer	4.56e-05	0.00105	CcSEcCtD
Dolutegravir—Diarrhoea—Etoposide—lung cancer	4.54e-05	0.00104	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Docetaxel—lung cancer	4.51e-05	0.00103	CcSEcCtD
Dolutegravir—Diarrhoea—Paclitaxel—lung cancer	4.45e-05	0.00102	CcSEcCtD
Dolutegravir—Dizziness—Etoposide—lung cancer	4.39e-05	0.00101	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—lung cancer	4.38e-05	0.00126	CbGpPWpGaD
Dolutegravir—Immune system disorder—Doxorubicin—lung cancer	4.38e-05	0.001	CcSEcCtD
Dolutegravir—Vertigo—Methotrexate—lung cancer	4.38e-05	0.001	CcSEcCtD
Dolutegravir—Abdominal pain—Docetaxel—lung cancer	4.36e-05	0.000998	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—lung cancer	4.32e-05	0.00124	CbGpPWpGaD
Dolutegravir—Dizziness—Paclitaxel—lung cancer	4.3e-05	0.000985	CcSEcCtD
Dolutegravir—Nausea—Cisplatin—lung cancer	4.3e-05	0.000985	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—lung cancer	4.24e-05	0.000972	CcSEcCtD
Dolutegravir—Vomiting—Etoposide—lung cancer	4.22e-05	0.000966	CcSEcCtD
Dolutegravir—Rash—Etoposide—lung cancer	4.18e-05	0.000958	CcSEcCtD
Dolutegravir—Dermatitis—Etoposide—lung cancer	4.18e-05	0.000957	CcSEcCtD
Dolutegravir—Headache—Etoposide—lung cancer	4.16e-05	0.000952	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A1—lung cancer	4.16e-05	0.0012	CbGpPWpGaD
Dolutegravir—Flatulence—Doxorubicin—lung cancer	4.16e-05	0.000952	CcSEcCtD
Dolutegravir—Vomiting—Paclitaxel—lung cancer	4.14e-05	0.000947	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.12e-05	0.000943	CcSEcCtD
Dolutegravir—Rash—Paclitaxel—lung cancer	4.1e-05	0.00094	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A1—lung cancer	4.1e-05	0.00118	CbGpPWpGaD
Dolutegravir—Dermatitis—Paclitaxel—lung cancer	4.1e-05	0.000939	CcSEcCtD
Dolutegravir—Headache—Paclitaxel—lung cancer	4.08e-05	0.000934	CcSEcCtD
Dolutegravir—Hypersensitivity—Docetaxel—lung cancer	4.06e-05	0.000931	CcSEcCtD
Dolutegravir—Asthenia—Docetaxel—lung cancer	3.96e-05	0.000906	CcSEcCtD
Dolutegravir—Nausea—Etoposide—lung cancer	3.94e-05	0.000903	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—lung cancer	3.9e-05	0.000894	CcSEcCtD
Dolutegravir—Nervous system disorder—Methotrexate—lung cancer	3.9e-05	0.000893	CcSEcCtD
Dolutegravir—Nausea—Paclitaxel—lung cancer	3.86e-05	0.000885	CcSEcCtD
Dolutegravir—Skin disorder—Methotrexate—lung cancer	3.86e-05	0.000884	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—lung cancer	3.79e-05	0.000868	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—lung cancer	3.77e-05	0.000864	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—COL4A3BP—lung cancer	3.66e-05	0.00105	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AZIN2—lung cancer	3.66e-05	0.00105	CbGpPWpGaD
Dolutegravir—Dizziness—Docetaxel—lung cancer	3.65e-05	0.000835	CcSEcCtD
Dolutegravir—Insomnia—Methotrexate—lung cancer	3.59e-05	0.000823	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.57e-05	0.000817	CcSEcCtD
Dolutegravir—Vomiting—Docetaxel—lung cancer	3.51e-05	0.000803	CcSEcCtD
Dolutegravir—Rash—Docetaxel—lung cancer	3.48e-05	0.000796	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—lung cancer	3.47e-05	0.000796	CcSEcCtD
Dolutegravir—Headache—Docetaxel—lung cancer	3.45e-05	0.000791	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Methotrexate—lung cancer	3.43e-05	0.000786	CcSEcCtD
Dolutegravir—Fatigue—Methotrexate—lung cancer	3.43e-05	0.000785	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—lung cancer	3.37e-05	0.000773	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—lung cancer	3.34e-05	0.000766	CcSEcCtD
Dolutegravir—Nausea—Docetaxel—lung cancer	3.28e-05	0.00075	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Methotrexate—lung cancer	3.25e-05	0.000744	CcSEcCtD
Dolutegravir—Abdominal pain—Methotrexate—lung cancer	3.14e-05	0.00072	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—lung cancer	3.11e-05	0.000713	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ATP5H—lung cancer	3.11e-05	0.000894	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—POMC—lung cancer	3.1e-05	0.000891	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—lung cancer	2.97e-05	0.000681	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—lung cancer	2.97e-05	0.00068	CcSEcCtD
Dolutegravir—Hypersensitivity—Methotrexate—lung cancer	2.93e-05	0.000671	CcSEcCtD
Dolutegravir—Asthenia—Methotrexate—lung cancer	2.85e-05	0.000653	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—lung cancer	2.81e-05	0.000645	CcSEcCtD
Dolutegravir—Pruritus—Methotrexate—lung cancer	2.81e-05	0.000644	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PLBD1—lung cancer	2.77e-05	0.000797	CbGpPWpGaD
Dolutegravir—Abdominal pain—Doxorubicin—lung cancer	2.72e-05	0.000623	CcSEcCtD
Dolutegravir—Diarrhoea—Methotrexate—lung cancer	2.72e-05	0.000623	CcSEcCtD
Dolutegravir—Dizziness—Methotrexate—lung cancer	2.63e-05	0.000602	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—lung cancer	2.54e-05	0.000581	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—HSD17B10—lung cancer	2.53e-05	0.000729	CbGpPWpGaD
Dolutegravir—Vomiting—Methotrexate—lung cancer	2.53e-05	0.000579	CcSEcCtD
Dolutegravir—Rash—Methotrexate—lung cancer	2.51e-05	0.000574	CcSEcCtD
Dolutegravir—Dermatitis—Methotrexate—lung cancer	2.5e-05	0.000573	CcSEcCtD
Dolutegravir—Headache—Methotrexate—lung cancer	2.49e-05	0.00057	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—lung cancer	2.47e-05	0.000566	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—lung cancer	2.43e-05	0.000558	CcSEcCtD
Dolutegravir—Nausea—Methotrexate—lung cancer	2.36e-05	0.000541	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CKB—lung cancer	2.36e-05	0.000678	CbGpPWpGaD
Dolutegravir—Diarrhoea—Doxorubicin—lung cancer	2.35e-05	0.000539	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—lung cancer	2.28e-05	0.000521	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CNDP2—lung cancer	2.21e-05	0.000637	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM2—lung cancer	2.21e-05	0.000637	CbGpPWpGaD
Dolutegravir—Vomiting—Doxorubicin—lung cancer	2.19e-05	0.000501	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—lung cancer	2.17e-05	0.000497	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—lung cancer	2.17e-05	0.000497	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—lung cancer	2.16e-05	0.000494	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—MTMR3—lung cancer	2.15e-05	0.00062	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PGAM1—lung cancer	2.1e-05	0.000604	CbGpPWpGaD
Dolutegravir—Nausea—Doxorubicin—lung cancer	2.04e-05	0.000468	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CYP2A7—lung cancer	2e-05	0.000576	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SDC4—lung cancer	1.96e-05	0.000564	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RRM1—lung cancer	1.79e-05	0.000514	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA3—lung cancer	1.79e-05	0.000514	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—B4GALT5—lung cancer	1.68e-05	0.000483	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA4—lung cancer	1.63e-05	0.00047	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA2—lung cancer	1.59e-05	0.000458	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA1—lung cancer	1.54e-05	0.000442	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCC3—lung cancer	1.52e-05	0.000437	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKR1C1—lung cancer	1.47e-05	0.000423	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GNG11—lung cancer	1.38e-05	0.000396	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDOA—lung cancer	1.31e-05	0.000377	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA3—lung cancer	1.27e-05	0.000366	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ADCY1—lung cancer	1.24e-05	0.000356	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCG2—lung cancer	1.24e-05	0.000356	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ENO2—lung cancer	1.21e-05	0.000349	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HPGDS—lung cancer	1.21e-05	0.000349	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPP2R1B—lung cancer	1.21e-05	0.000347	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—lung cancer	1.18e-05	0.000339	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2A6—lung cancer	1.16e-05	0.000335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GCLC—lung cancer	1.16e-05	0.000335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ENO1—lung cancer	1.1e-05	0.000317	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2E1—lung cancer	9.89e-06	0.000285	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NQO1—lung cancer	9.78e-06	0.000281	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—STK11—lung cancer	8.82e-06	0.000254	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—lung cancer	8.16e-06	0.000235	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CAT—lung cancer	7.94e-06	0.000228	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCB1—lung cancer	7.72e-06	0.000222	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMS—lung cancer	7.58e-06	0.000218	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—lung cancer	7.5e-06	0.000216	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A1—lung cancer	7.11e-06	0.000204	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ERCC2—lung cancer	7.05e-06	0.000203	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—APOA1—lung cancer	6.1e-06	0.000175	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CG—lung cancer	5.57e-06	0.00016	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—POMC—lung cancer	5.3e-06	0.000152	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CREBBP—lung cancer	5.16e-06	0.000148	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CD—lung cancer	4.89e-06	0.000141	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALB—lung cancer	4.83e-06	0.000139	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CB—lung cancer	4.27e-06	0.000123	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—lung cancer	4.23e-06	0.000122	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—lung cancer	3.69e-06	0.000106	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—EP300—lung cancer	3.52e-06	0.000101	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—lung cancer	2.6e-06	7.48e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—lung cancer	2.12e-06	6.11e-05	CbGpPWpGaD
